Supplementary Figure 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
作者
Patricia LoRusso,Jing Li,Angelika M. Burger,Lance K. Heilbrun,Edward A. Sausville,Scott A. Boerner,Daryn Smith,Mary Jo Pilat,Jie Zhang,Sara M. Tolaney,James M. Cleary,Alice P. Chen,Larry Rubinstein,Julie L. Boerner,Adam Bowditch,Dongpo Cai,Tracy Bell,Andrew Wolanski,Allison M. Marrero,Yiping Zhang